Taxotere (Docetaxel) Eye Injury Products Liability Litigation
The causation theory is based on the neurotoxic and inflammatory effects of Docetaxel, which can be secreted into tears, causing inflammation, fibrosis, and scarring of the lacrimal system. This results in punctal and canalicular obstructions, leading to tear drainage issues and vision problems. Scientific evidence supports that the drug's presence in tears directly damages the epithelial tissues of the lacrimal ducts, causing permanent injury.
142
Pending actions
433
Total actions filed
Active
Status
02/01/2022
Established
Filing deadline
The deadline for individual plaintiffs to join or file claims is July 15, 2026, which is 180 days from the court order date of January 16, 2026.
Who qualifies
Plaintiffs must have used Taxotere during chemotherapy treatment, with exposure typically exceeding standard doses over a treatment course of several months. Injuries such as punctal, canalicular, or lacrimal duct damage must manifest within 6 months to 1 year post-treatment, supported by medical evidence linking the injury to Taxotere use. The injury must be documented through ophthalmologic assessments, with a demonstrated causal link established by medical and legal evidence.
Products involved
- Taxotere
- Docetaxel
Alleged injuries
- permanent eye damage
- lacrimally system injuries
- punctal and canalicular injuries
- vision loss
Bellwether trials
There are no specific dates or schedules for bellwether trials as of April 2026. Recent rulings have granted summary judgments to some defendants, and no recent verdicts have been reported. Settlement estimates range from $20,000 to over $400,000 depending on injury severity, but no confirmed payouts have occurred.
Settlement landscape
Potential settlement ranges are estimated between $20,000 and over $400,000 depending on injury severity and case specifics. No confirmed settlements or payouts have been reported as of early 2026.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
